Research Applications
Alzheimer's disease (preclinical). Adult neurogenesis enhancement. Tau pathology reduction. Cognitive decline prevention.
Mechanism of Action
P21 increases BDNF expression through CNTF receptor (CNTFR/LIFRβ/gp130) signaling. It inhibits leukemia inhibitory factor (LIF) signaling, relieving its suppression of neurogenesis. P21 also inhibits GSK-3β, reducing tau hyperphosphorylation and promoting β-catenin-mediated neurogenesis.
Biological Pathways
Neurogenesis, Cognitive enhancement, Neuroprotection
Dosage Information
Calculation Results
Syringe Fill Level (100u syringe)
Protocols
No protocols featuring this peptide yet.
Browse All ProtocolsRegulatory Status
Very limited human data. Experimental compound
Research Studies
P21 Promotes Neurogenesis and Reduces Tau Pathology
Bolognin S, Buffelli M, Bhatt N, et al.
Frequently Asked Questions
P21 (also called Cerebrolysin-derived peptide P021) is a small tetrapeptide derivative (Ac-DGGL) based on an active region of ciliary neurotrophic factor (CNTF) that promotes neurogenesis and inhibits neurodegeneration. Unlike full-length CNTF, P21 is orally bioavailable and crosses the blood-brain barrier. Preclinical studies show it enhances dentate gyrus neurogenesis, reduces tau pathology, and improves cognitive function in Alzheimer's disease models through dual mechanisms: BDNF/TrkB upregulation and GSK-3β inhibition.
P21 increases BDNF expression through CNTF receptor (CNTFR/LIFRβ/gp130) signaling. It inhibits leukemia inhibitory factor (LIF) signaling, relieving its suppression of neurogenesis. P21 also inhibits GSK-3β, reducing tau hyperphosphorylation and promoting β-catenin-mediated neurogenesis.
Alzheimer's disease (preclinical). Adult neurogenesis enhancement. Tau pathology reduction. Cognitive decline prevention.
Neurogenesis, Cognitive enhancement, Neuroprotection
Very limited human data. Experimental compound
